Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Payables (2020 - 2025)

HCW Biologics (HCWB) has disclosed Payables for 6 consecutive years, with $6.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables fell 8.18% year-over-year to $6.9 million, compared with a TTM value of $6.9 million through Sep 2025, down 8.18%, and an annual FY2024 reading of $7.3 million, up 18.31% over the prior year.
  • Payables was $6.9 million for Q3 2025 at HCW Biologics, down from $25.8 million in the prior quarter.
  • Across five years, Payables topped out at $25.8 million in Q2 2025 and bottomed at $296207.0 in Q2 2022.
  • Average Payables over 5 years is $5.4 million, with a median of $3.0 million recorded in 2023.
  • The sharpest move saw Payables crashed 70.29% in 2022, then soared 697.53% in 2024.
  • Year by year, Payables stood at $2.1 million in 2021, then dropped by 17.52% to $1.7 million in 2022, then surged by 256.42% to $6.2 million in 2023, then grew by 18.31% to $7.3 million in 2024, then fell by 5.11% to $6.9 million in 2025.
  • Business Quant data shows Payables for HCWB at $6.9 million in Q3 2025, $25.8 million in Q2 2025, and $7.4 million in Q1 2025.